🇺🇸 ABBV — AbbVie Inc.

Salud Compra
← Volver

Precio actual

286,00 USD

Máx. histórico

294,89

4 días

Caída desde máximo

-3,01%

Rango 52 semanas

190,75 – 298,74

Variación hoy

-0,98%

Cierre anterior

288,84

Rango de hoy

284,71 – 291,32

Volumen hoy

5.348.839

Peor caída histórica

-45,09%

26/01/2018 → 15/08/2019

Recuperado en 477 días

Volatilidad anualizada ⓘ

26,29%

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
49,14 (puede no estar actualizado)
Dividend yield
2,40% (puede no estar actualizado)
Precio objetivo analistas
306,42 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 2 horas
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,9200 USD · Yield: 2,42%
Fecha de pago Importe por participación
15/10/2026 1,7300 USD
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/11/2025 235,00 237,19 232,11 233,87 -0,06% 2,16% 6.232.600
17/11/2025 233,26 235,35 229,23 234,00 +0,71% 2,62% 5.023.100
14/11/2025 233,61 235,00 230,32 232,36 +0,03% 2,00% 5.461.500
13/11/2025 233,74 239,29 232,16 232,29 -0,40% 3,05% 7.968.500
12/11/2025 225,40 234,00 225,29 233,23 +3,58% 3,86% 8.583.200
11/11/2025 219,00 225,42 219,00 225,17 +2,95% 2,93% 4.802.400
10/11/2025 217,00 219,86 216,15 218,71 -0,21% 1,71% 4.530.800
07/11/2025 219,31 220,99 217,09 219,16 +0,05% 1,78% 4.647.900
06/11/2025 215,89 219,68 215,65 219,04 +1,05% 1,87% 6.615.300
05/11/2025 215,74 217,43 212,60 216,77 +0,41% 2,24% 4.928.200
04/11/2025 212,37 217,08 212,37 215,89 +1,85% 2,22% 6.184.000
03/11/2025 216,68 219,00 211,69 211,96 -2,79% 3,37% 8.874.300
31/10/2025 223,00 223,87 216,00 218,04 -4,45% 3,53% 10.825.300
30/10/2025 227,05 229,65 226,41 228,20 +1,36% 1,43% 5.020.700
29/10/2025 227,62 228,00 224,04 225,14 -1,05% 1,74% 5.469.300
28/10/2025 227,00 228,40 224,31 227,54 -0,21% 1,80% 3.724.200
27/10/2025 227,95 228,60 227,12 228,03 +0,02% 0,65% 2.784.400
24/10/2025 228,78 229,04 226,25 227,99 -0,11% 1,22% 3.554.700
23/10/2025 228,99 229,86 227,25 228,25 -0,19% 1,14% 5.818.000
22/10/2025 231,67 232,16 228,43 228,68 -1,17% 1,61% 3.523.500
21/10/2025 232,15 232,81 229,83 231,39 -0,29% 1,28% 3.298.100
20/10/2025 231,00 232,26 230,00 232,06 +1,08% 0,98% 5.246.700
17/10/2025 227,52 230,71 226,81 229,57 +1,19% 1,71% 7.150.000
16/10/2025 226,22 228,11 225,46 226,87 +0,29% 1,17% 4.737.500
15/10/2025 227,20 228,95 225,32 226,22 -1,27% 1,60% 5.459.400
14/10/2025 228,07 230,65 227,51 229,13 -0,51% 1,38% 5.527.600
13/10/2025 230,00 233,81 229,22 230,30 -0,09% 2,00% 5.411.900
10/10/2025 231,51 234,68 230,50 230,50 -0,08% 1,81% 6.156.900
09/10/2025 233,27 233,79 230,62 230,69 -0,24% 1,36% 4.607.600
08/10/2025 231,48 233,00 229,68 231,24 -0,68% 1,43% 5.412.800